Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Avelox · 7 trials · 9 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Avelox (Moxifloxacin, BAY12-8039) | DRUG | Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days. |
| Amoxicilline/clavulanic | DRUG | IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days |
| Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin | DRUG | IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet. |
| Ceftriaxone + Metronidazole | DRUG | Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h |
| Placebo | DRUG | Matching placebo capsules orally once daily for 5 days every 8 weeks. |
| Levofloxacin + Ceftriaxone | DRUG | Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days). |
| Sulbactam/Ampicillin | DRUG | Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid |
Inclusion Criteria: * Written informed consent * Men or women of age \>/= 18 years with a diagnosis of bacterial skin and skin structure infection that requires * Hospitalization * Initial parenteral therapy for at least 48 hours * Complicated by at least one of the following criteria: * In...
Avelox is an antibiotic used for infections, including complicated intra-abdominal infections, aspiration pneumonia, and lung abscess. It has also been studied for preventing acute exacerbations in chronic bronchitis. Avelox is a small molecule developed by Bayer AG.
Avelox targets bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication. By inhibiting these targets, Avelox exerts its antibacterial effect. This mechanism is based on its classification as a fluoroquinolone antibiotic.
Avelox is developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY on the OTC market. The drug is a small molecule antibiotic.
Avelox is in Phase 3 clinical development. It has completed multiple Phase 3 trials, including studies for chronic bronchitis, complicated intra-abdominal infections, and aspiration pneumonia. Avelox is investigational and not yet approved for these indications.
Avelox has been studied in several clinical trials. NCT00473460 evaluated intermittent therapy for chronic bronchitis prevention. NCT00769171 studied treatment for complicated intra-abdominal infections. NCT01014247 assessed QTc interval effects. NCT01045902 investigated pulmonary abscess and aspiration pneumonia.
Yes, Avelox is the brand name for moxifloxacin, a fluoroquinolone antibiotic. Clinical trials listed under Avelox often use moxifloxacin as the drug name. This includes studies like NCT00473460 and NCT00769171, which refer to moxifloxacin therapy.